axicabtagene ciloleucel
gilead
['zuma-7', 'axi-cel', 'ts,perio,i']
in zuma-7, axi-cel significantly improved 4-year os in r/r lbcl with hr 0.726 despite 57% of patients in hdt-asct arm receiving 3l+ cellular therapy off protocol, establishing the superiority of car-t in earlier lines of therapy. #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.